ACM
ABBV icon

Advisors Capital Management’s AbbVie ABBV Stock Holding History

Advisors Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$131M Sell
601,587
-32,655
-5% -$7.24M 1.52% 6
2025
Q4 		$145M Buy
634,242
+20,147
+3% +$4.59M 1.7% 6
2025
Q3 		$142M Buy
614,095
+22,999
+4% +$4.68M 1.76% 5
2025
Q2 		$110M Buy
591,096
+11,317
+2% +$2.1M 1.5% 9
2025
Q1 		$121M Buy
579,779
+12,221
+2% +$2.38M 1.88% 4
2024
Q4 		$101M Buy
567,558
+12,381
+2% +$2.28M 1.59% 8
2024
Q3 		$110M Buy
555,177
+9,211
+2% +$1.72M 1.78% 6
2024
Q2 		$93.6M Buy
545,966
+20,174
+4% +$3.34M 1.63% 6
2024
Q1 		$95.7M Buy
525,792
+23,518
+5% +$4.05M 1.75% 5
2023
Q4 		$77.8M Buy
502,274
+5,143
+1% +$750K 1.58% 6
2023
Q3 		$74.1M Buy
497,131
+15,353
+3% +$2.25M 1.88% 5
2023
Q2 		$64.9M Sell
481,778
-6,089
-1% -$893K 1.55% 6
2023
Q1 		$77.8M Buy
487,867
+2,663
+0.5% +$407K 2.01% 4
2022
Q4 		$78.4M Sell
485,204
-17,640
-4% -$2.7M 2.13% 4
2022
Q3 		$76.3M Buy
502,844
+10,979
+2% +$1.58M 2.04% 4
2022
Q2 		$75.3M Sell
491,865
-5,192
-1% -$793K 2.29% 4
2022
Q1 		$80.6M Buy
497,057
+8,333
+2% +$1.21M 2.2% 4
2021
Q4 		$66.2M Buy
488,724
+77,415
+19% +$9.14M 1.8% 5
2021
Q3 		$44.4M Buy
411,309
+18,720
+5% +$2.14M 1.35% 9
2021
Q2 		$44.2M Buy
392,589
+2,965
+0.8% +$334K 1.4% 10
2021
Q1 		$42.2M Buy
389,624
+126,047
+48% +$13.5M 1.48% 10
2020
Q4 		$28.2M Buy
263,577
+9,115
+4% +$876K 1.08% 22
2020
Q3 		$22.3M Sell
254,462
-550
-0.2% -$51.8K 1.04% 29
2020
Q2 		$25M Buy
255,012
+246,781
+2,998% +$21.7M 1.24% 20
2020
Q1 		$627K Buy
8,231
+4,359
+113% +$371K 0.04% 190
2019
Q4 		$343K Buy
+3,872
New +$321K 0.02% 283

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Advisors Capital Management's ABBV Position: Q1 2026 in Review

Advisors Capital Management reduced its AbbVie (ABBV) stake by 5.1% in Q1 2026, selling an estimated $7.24M and leaving 601,587 shares worth $131M. The position accounts for 1.52% of the portfolio, ranked #6.

Advisors Capital Management first reported a position in ABBV in Q4 2019 and has held it in 26 quarters since. The position peaked at $145M in Q4 2025. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Advisors Capital Management held 601,587 shares of AbbVie worth $131M as of Q1 2026.
  • Advisors Capital Management sold 32,655 AbbVie shares in Q1 2026, an estimated $7.24M.
  • AbbVie made up 1.52% of Advisors Capital Management's portfolio in Q1 2026, its #6 holding.
  • Advisors Capital Management first reported a position in AbbVie in Q4 2019 and has held it in 26 quarters since.
  • Advisors Capital Management's AbbVie position peaked at $145M in Q4 2025.
  • 4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Advisors Capital Management's 13F filing for Q1 2026, filed 1 May 2026.